Tobira Therapeutics announced that it closed a four year, $15 million term loan facility with Oxford Finance. The facility will support the development of CVC for the treatment of nonalcoholic steatohepatitis and for working capital and general corporate needs.

Tobira Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, HIV, fibrosis and inflammation.